Mode
Text Size
Log in / Sign up
N/A N=281 Randomized Single-blind Prevention

Maternal-Offspring Metabolics:Family Intervention Trial

Pregnancy · Weight Gain

Enrolled (actual)
281
Serious AEs
16.7%
Results posted
Sep 2018
Primary outcome: Primary: Gestational Weight Gain (GWG) — 12; 10 kg — p=0.01

Study Design & Population

Study type
Interventional
Phase
N/A
Interventions
Lifestyle Intervention Group (Behavioral); Usual Care Group (Behavioral)
Age
Adult · 18+ yrs
Sex
Female
Sponsor
Northwestern University
Primary completion
Jul 2017

Outcome Measures

OutcomeResultp-value
PRIMARY
Gestational Weight Gain (GWG)
12; 10 0.01 sig
SECONDARY
Percentage of Participants With Gestational Diabetes
9; 7 0.54
SECONDARY
Fasting Glucose
87; 86; 85; 84 0.89
SECONDARY
High-density Lipoprotein (HDL)
66; 71; 68; 70 0.30
SECONDARY
Low-density Lipoprotein (LDL)
95; 94; 146; 130 0.69
SECONDARY
Total Cholesterol
188; 185; 255; 252 0.19
SECONDARY
Triglycerides
108; 109; 235; 223 0.27
SECONDARY
Leptin
49; 50; 59; 54 0.003 sig
SECONDARY
Steady State Beta Cell Function
120; 121; 174; 159 0.24
SECONDARY
Insulin Sensitivity
78; 87; 51; 62 0.32
SECONDARY
Insulin Resistance (IR)
1.3; 1.2; 2.0; 1.6 0.26
SECONDARY
Birth Weight
3213; 3244 0.62
SECONDARY
Birth Length
51; 51 0.61
SECONDARY
Head Circumference
34; 34 0.42
SECONDARY
Neonate Percent Body Fat
11.9; 11.2 0.25
SECONDARY
Infant Weight
9.9; 9.9 0.66
SECONDARY
Infant Length
76.3; 76.2 0.94

Summary

The prevalence of maternal overweight and obesity has nearly doubled in the United States since 1976. In 2004-2005, 42% of pregnant women had body mass index (BMI) above 25 versus 23% in 1993. Most American women are overweight/ obese (OW/OB) at conception, especially within certain racial, ethnic, and lower socioeconomic groups leading to increased adverse maternal and birth outcomes. This study will recruit, randomize and test in 300 ethnically diverse OW/OB pregnant women a behavioral intervention aimed at controlling gestational weight gain (GWG) through recommended diet, activity and lifestyle changes that are to be maintained postpartum. Outcomes include anthropometric (height, weight, percent body fat) metabolic (blood pressure, fasting glucose, insulin, HbA1c, lipids and C-reactive protein) and behavioral measures (diet. physical activity, sleep and stress). In addition, babies will be measured for length, weight and percent body fat. The goal is to limit excessive gestational weight gain through improved maternal lifestyle that can be maintained and modelled for the family post partum and beyond.

Eligibility Criteria

Inclusion Criteria

  • Age 18-45 years
  • Singleton viable pregnancy. A twin pregnancy reduced to singleton before 14 weeks by project gestational age. An ultrasound must be conducted before randomization that shows a fetal heartbeat; there should be no evidence of more than one fetus on the most recent pre-randomization ultrasound.
  • Gestational age at randomization no earlier than 9 weeks 0 days and no later than 15 weeks 6 days based on an algorithm (see Section 3.4.3 below) that compares the last menstrual period (LMP) date and data from the earliest ultrasound
  • Body mass index between 25-35 kg/m2 based on first trimester measured weight and on measured height. The earliest weight measurement before randomization, measured specifically for the study will be used.

Exclusion Criteria

  • In vitro fertilization (IVF) conception/ovulation induction w/ gonadotropins
  • Weight gain of >15 pounds from reported prepregnancy weight to Baseline visit
  • Current smoker
  • Prior bariatric surgery
  • In weight loss program w/in 3 months of conception
  • History of alcohol or drug abuse within 5 years
  • No access to internet and/or smartphone
  • Unable to attend intervention/follow-up visits
  • Unwilling/unable to commit to self-monitoring data collection
  • Unable to complete intervention program
  • Presence of any condition that limits walking or following diet recommendations
  • Not fluent in English
View full record on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov (NCT01631747). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.

Back to search